Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib

Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woma...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Nobuyoshi, Fujita, Akihisa, Saikai, Toyohiro, Takabatake, Hirotugu, Sotoshiro, Mie, Sekine, Kyuutarou, Kawana, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874345/
https://www.ncbi.nlm.nih.gov/pubmed/29151522
http://dx.doi.org/10.2169/internalmedicine.9368-17
_version_ 1783310147726082048
author Hayashi, Nobuyoshi
Fujita, Akihisa
Saikai, Toyohiro
Takabatake, Hirotugu
Sotoshiro, Mie
Sekine, Kyuutarou
Kawana, Akihiko
author_facet Hayashi, Nobuyoshi
Fujita, Akihisa
Saikai, Toyohiro
Takabatake, Hirotugu
Sotoshiro, Mie
Sekine, Kyuutarou
Kawana, Akihiko
author_sort Hayashi, Nobuyoshi
collection PubMed
description Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a partial response.
format Online
Article
Text
id pubmed-5874345
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-58743452018-03-29 Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib Hayashi, Nobuyoshi Fujita, Akihisa Saikai, Toyohiro Takabatake, Hirotugu Sotoshiro, Mie Sekine, Kyuutarou Kawana, Akihiko Intern Med Case Report Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a partial response. The Japanese Society of Internal Medicine 2017-11-20 2018-03-01 /pmc/articles/PMC5874345/ /pubmed/29151522 http://dx.doi.org/10.2169/internalmedicine.9368-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hayashi, Nobuyoshi
Fujita, Akihisa
Saikai, Toyohiro
Takabatake, Hirotugu
Sotoshiro, Mie
Sekine, Kyuutarou
Kawana, Akihiko
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
title Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
title_full Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
title_fullStr Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
title_full_unstemmed Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
title_short Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
title_sort large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (alk) rearrangement with response to alectinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874345/
https://www.ncbi.nlm.nih.gov/pubmed/29151522
http://dx.doi.org/10.2169/internalmedicine.9368-17
work_keys_str_mv AT hayashinobuyoshi largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib
AT fujitaakihisa largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib
AT saikaitoyohiro largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib
AT takabatakehirotugu largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib
AT sotoshiromie largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib
AT sekinekyuutarou largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib
AT kawanaakihiko largecellneuroendocrinecarcinomaharboringananaplasticlymphomakinasealkrearrangementwithresponsetoalectinib

Ejemplares similares